SecBot SecBot
8-K ·Filed Aug 5, 2026

LIVN

LivaNova PLC
BULLISH
Impact 7/10
Horizondays Processed3mo ago SEC0001639691-26-000085
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat and guidance raise confirm accelerating momentum in core businesses. The lowered free cash flow guidance is a minor offset, reflecting investment for growth. Traders should watch the upcoming earnings call for details on the Thermo Fisher supply agreement and OSA market entry timeline.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$78.15
T+0 close · Aug 5, 2026 · via day close
Latest settled
+4.32%
T+60 · $81.52
Vs SPY
+4.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $78.15entry
  2. T+1 · 3mo ago −3.03%α −2.87% · $75.78
  3. T+5 · 3mo ago +3.37%α +3.02% · $80.78
  4. T+20 · 3mo ago +5.45%α +6.05% · $82.40
  5. T+60 · 19d ago +4.32%α +4.13% · $81.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

LivaNova reported Q2 2026 revenue of $390.6M (+10.8% YoY) and adjusted diluted EPS of $1.26, beating consensus estimates of $1.09 by 15.6%. The company raised full-year 2026 revenue growth guidance to 8%-9% (from 7%-8%) and adjusted EPS guidance to $4.30-$4.40 (from $4.20-$4.30), reflecting strong execution in Cardiopulmonary and Neuromodulation. A favorable Italian tax ruling generated a $95.4M discrete benefit, boosting GAAP EPS to $1.93, but the core beat and guidance raise are the primary drivers for the stock.

Key Financial Metrics

EPS
$1.26
est $1.09 · +15.6%
Revenue
$390.6M
est $380.6M · +2.6% · +10.8% YoY
Rating
beat
Guidance
8% to 9% constant-currency growth
raised
Free Cash Flow
$45.5M
Gross Margin
70.1%

Key Facts

  • Q2 2026 revenue of $390.6M (+10.8% reported, +9.8% constant-currency) beat consensus of $380.6M.
  • Adjusted diluted EPS of $1.26 beat consensus of $1.09 by 15.6%.
  • Full-year 2026 revenue growth guidance raised to 8%-9% constant-currency (from 7%-8%).
  • Full-year 2026 adjusted EPS guidance raised to $4.30-$4.40 (from $4.20-$4.30).
  • Cardiopulmonary revenue grew 11.2% reported; Neuromodulation grew 10.1% reported.
  • Received a favorable Italian tax ruling, recognizing a $95.4M discrete tax benefit.
  • Adjusted free cash flow guidance lowered to $140M-$160M (from $160M-$180M) due to strategic investments.

Financial Impact

Revenue beat of ~$10M vs consensus; EPS beat of $0.17 vs consensus; guidance raise adds ~$0.10 to midpoint of full-year EPS.

revenueepsguidance

Risk Factors

  • Lowered adjusted free cash flow guidance ($140M-$160M vs prior $160M-$180M) signals higher capex.
  • Foreign exchange headwinds and supply chain risks remain.
  • Execution risk on OSA market entry and Cardiopulmonary capacity expansion.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001639691-26-000085
Document: livn-20260805.htm0001639691-26-000085
Document: 0001639691-26-000085-index-headers.html0001639691-26-000085
Document: 0001639691-26-000085-index.html0001639691-26-000085
Document: 0001639691-26-000085.txt0001639691-26-000085
8-K Data (Synthetic)0001639691-26-000085

Track record

10 reports on LIVN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $94.19 Now $92.44 −1.86% settles Feb 2
  5. Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
  6. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
  7. Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
  8. May 6, 202627w ago 8-K Bullish 8/10 Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
  9. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
  10. Feb 25, 202637w ago 8-K Bullish 7/10 Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026